MedTrace Logo

A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

NCT06660173 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 409

Last updated 2025-11-25

No results posted yet for this study

Summary

The main purpose of this study is to assess the dose-response relationship of maridebart cafraglutide on glucose control compared with placebo.

Conditions

  • Type 2 Diabetes Mellitus (T2DM)

Interventions

DRUG

Maridebart Cafraglutide

Solution for subcutaneous injection.

DRUG

Placebo

Solution for subcutaneous injection.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-07
Primary Completion
2025-10-06
Completion
2026-11-10
FDA Drug
Yes

Countries

  • United States
  • Austria
  • Greece
  • Hong Kong
  • Hungary
  • Italy
  • Japan
  • Poland
  • Puerto Rico
  • Romania
  • South Korea
  • Spain
  • Sweden
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06660173 on ClinicalTrials.gov